Drugs /

tas0953/hm06

Back to Drugs List

Overview

NCI Definition [1]:
An orally bioavailable selective inhibitor of wild-type, fusion products and mutated forms of the proto-oncogene receptor tyrosine kinase rearranged during transfection (RET), with potential antineoplastic activity. Upon oral administration, the RET inhibitor TAS0953/HM06 selectively binds to and inhibits the activity of RET. This results in an inhibition of cell growth of tumors cells that exhibit increased RET activity. RET overexpression, activating mutations, and fusions result in the upregulation and/or overactivation of RET tyrosine kinase activity in various cancer cell types; dysregulation of RET activity plays a key role in the development and progression of these cancers.

Clinical Trials

View Clinical Trials for tas0953/hm06

Tas0953/hm06 has been investigated in 1 clinical trial, of which 1 is open and 0 are closed. Of the trial investigating tas0953/hm06, 1 is phase 1/phase 2 (1 open).

RET Fusion and RET Mutation are the most frequent biomarker inclusion criteria for tas0953/hm06 clinical trials.

Malignant solid tumor is the most common disease being investigated in tas0953/hm06 clinical trials [2].

Top Biomarker Inclusion Criteria for Open Clinical Trials Investigating Tas0953/hm06
This graph displays the 20 most frequently occurring biomarkers curated on clinical trials investigating tas0953/hm06 and the cancer types associated with these biomarkers. These numbers are derived from a set of 5,956 clinical trials for which biomarker status defines treatment.

Drug Details

Synonyms [2]:
ret inhibitor tas0953/hm06
NCIT ID [1]:
C176968

References

1. National Cancer Institute. NCI Thesaurus Version 18.11d. https://ncit.nci.nih.gov/ncitbrowser/. [2018-07-30] [2018-08-02].

2. All assertions and clinical trial landscape data are curated from primary sources. You can read more about the curation process here.